Back to discover
Drug

Bleomycin

In clinical development
Emerging researchLate-stage development

Also known as Bleomicin, Bleomicina, Bleomycinum.

RxNorm1622ChEMBLCHEMBL6067492ATCL01DC01UNII40S1VHN69B
1
Research papers
17
Active clinical trials
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Injection Sclerotherapy With Bleomycin VS Doxycycline in Patients With Lymphatic Malformations:A Randomized Controlled Trial

Clinical trial2026-07-26Primary completion · ClinicalTrials.gov

A Randomised Phase III Trial With a PET Response Adapted Design Comparing ABVD +/- ISRT With A2VD +/- ISRT in Patients With Previously Untreated Stage IA/IIA Hodgkin Lymphoma

Clinical trial2026-07-08Results expected Q3 2030 · ClinicalTrials.gov

Randomized Phase II Trial of Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-Risk Germ Cell Tumors

Clinical trial2026-07-06Results expected Q2 2027 · ClinicalTrials.gov

A Self-controlled Study of Bleomycin and Pingyangmycin Injection in the Treatment of Plantar Warts

Clinical trial2026-07-02Results expected Q4 2026 · ClinicalTrials.gov

Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17

Clinical trial2026-06-17Results expected Q1 2027 · ClinicalTrials.gov

A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

Clinical trial2026-02-27Results posted · ClinicalTrials.gov

An Open-label, Uncontrolled, Multicenter Phase II Trial of MK-3475 (Pembrolizumab) in Children and Young Adults With Newly Diagnosed Classical Hodgkin Lymphoma With Inadequate (Slow Early) Response to Frontline Chemotherapy (KEYNOTE 667)

Clinical trial2026-02-19Results expected Q4 2026 · ClinicalTrials.gov

Phase I/II of Nivolumab and A(B)VD in the Front-line Setting for High Risk Hodgkin Lymphoma

Clinical trial2026-02-17Results expected Q1 2027 · ClinicalTrials.gov

Efficacy and Safety of Different Concentrations of Bleomycin in the Sclerotherapy of Lymphatic Malformations for Pediatric Patients

Clinical trial2025-12-31Primary completion · ClinicalTrials.gov

Comparison of the Efficacy of Microneedling Alone Versus Microneedling Coupled With Either Bleomycin or 5flourouracil in the Treatment of Plantar Warts

Clinical trial2025-06-27Results expected Q2 2027 · ClinicalTrials.gov

Phase 3 Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Clinical trial2025-06-15Results expected Q4 2029 · ClinicalTrials.gov

Estimating the global burden of Epstein-Barr virus-related cancers.

Research2021-10-27Journal of cancer research and clinical oncology

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Bleomycin
Aliases & brands
BleomicinBleomicinaBleomycinum
RxNorm CUI
1622
ChEMBL ID
CHEMBL6067492
ATC codes
L01DC01
UNII
40S1VHN69B

Clinical trials

61 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
61
registered trials across all phases
LATEST COMPLETION 2026
17
Active studies
10
Recruiting
26
Late-stage (III+)
26
Completed
18
Discontinued
PHASE DISTRIBUTIONn = 61
Phase 15Phase 1 / 21Phase 229Phase 318Phase 46Phase N / A2

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Randomised Controlled Clinical Trial Investigating the Effect of Reduced Bleomycin in Elechtrochemotherapy Treatment on Patients With Cutaneous Malignancies (The BLESS Trial)

RecruitingPH IVJulie Gehln=552027

A Self-controlled Study of Bleomycin and Pingyangmycin Injection in the Treatment of Plantar Warts

Active, not recruitingPH IVSecond Affiliated Hospital, School of Medicine, Zhejiang Universityn=2002026

Compare the Effect of Bleomycin and Tetradecyl Sodium Sulphate in the Treatment of Venous Malformations

Unknown statusPH IVOslo University Hospitaln=1352025

Intralesional Bleomycin Treatment of Keloids Using an Electronic Pneumatic Jet Injector: a Double-blind Randomized, Placebo-controlled Trial With Split-lesion Design

Unknown statusPH IVErasmus Medical Centern=142023

Bleomycin Infusion (MMP®) to Repigment Achromic Scars

Unknown statusPH IVClinica Dermatologica Arbache ltdan=502020

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Randomized, Open-label, Phase 3 Trial of A+AVD Versus ABVD as Frontline Therapy in Patients With Advanced Classical Hodgkin Lymphoma

CompletedPH IIIKey trialTakedan=1,3342026

A Randomized, Open-label, Multicenter, Phase III, 2-arm Study Comparing Efficacy and Tolerability of the Intensified Variant 'Dose-dense/Dose-intense ABVD' (ABVD DD-DI) With an Interim PET Response-adapted ABVD Program as Upfront Therapy in Advanced-stage Classical Hodgkin Lymphoma (HL).

CompletedPH IIIFondazione Italiana Linfomi - ETSn=5002024

Phase 2 Study of Pembrolizumab and Chemotherapy in Patients With Newly Diagnosed Classical Hodgkin Lymphoma (KEYNOTE-C11)

CompletedPH IIMerck Sharp & Dohme LLCn=1462024

Stanford V Chemotherapy With Low-Dose Tailored-Field Radiation Therapy for Intermediate Risk Pediatric Hodgkin Lymphoma

CompletedPH IISt. Jude Children's Research Hospitaln=812022

Brentuximab Vedotin Associated With Chemotherapy in Untreated Patients With Stage I/II Unfavourable Hodgkin Lymphoma. A Randomized Phase II LYSA-FIL-EORTC Intergroup Study

CompletedPH IIThe Lymphoma Academic Research Organisationn=1702022

Intralesional Bleomycin Versus Cryotherapy for Treatment of Cutaneous Warts

CompletedPH IIJinnah Postgraduate Medical Centren=1542021

Research activity

1 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Most influential

Estimating the global burden of Epstein-Barr virus-related cancers.

Journal of cancer research and clinical oncology · 2022 · 216 cites
Recent papers

Estimating the global burden of Epstein-Barr virus-related cancers.

Journal of cancer research and clinical oncology · 2022 · 216 cites
Journals, researchers & institutions
Top journals
  • Journal of cancer research and clinical oncology1
Leading researchers
  • Burrows SR1
  • Doolan DL1
  • Meehan MT1
  • Miles JJ1
  • Wong Y1
Leading institutions
free-text, unnormalised
  • Australian Institute of Tropical Health and Medicine1
  • Centre for Molecular Therapeutics1
  • Centre for Tropical Bioinformatics and Molecular Biology1
  • QIMR Berghofer Medical Research Institute1
  • The University of Queensland1

Related drugs

3 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Dacarbazine

Studied across 9 of the same disease areas as Bleomycin in the shared literature.

9 shared diseases1 shared paper
Doxorubicin

Studied across 9 of the same disease areas as Bleomycin in the shared literature.

9 shared diseases1 shared paper
Vinblastine

Studied across 9 of the same disease areas as Bleomycin in the shared literature.

9 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials